Multiple Myeloma News

Here are all the latest news articles written by The Beacon’s staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (rocilinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), MOR202, oprozomib, panobinostat, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.

[ by | Aug 17, 2014 4:10 pm | 5 Comments ]
Kyprolis Fails To Provide Overall Survival Benefit In FOCUS Phase 3 Trial

Amgen has given a first glimpse of key results from its FOCUS Phase 3 clinical trial testing Kyprolis in relapsed and refractory multiple myeloma patients.

The company reported this past Wednesday that Kyprolis did not provide an overall survival advantage in the trial, which is being con­ducted out­side the United States.

In addition, the company noted that patients treated with Kyprolis during the trial experienced more kidney-related side effects than patients who were not treated with the drug.

Up until recently, the primary significance of the FOCUS trial would have …

Read the full story »
[ by | Aug 11, 2014 4:48 pm | 21 Comments ]
Remembering Stephen Kramer

Another valued voice of the myeloma community has been lost.

Stephen P. Kramer, author of the Beacon column “Manhattan Tales,” passed away last Friday, August 8, at Memorial Sloan-Kettering Cancer Center in New York City. Stephen was 66 years old, and was diagnosed with multiple myeloma in early 2010.

At the time of his diagnosis, Stephen was working as Chief of Staff and Special Counsel to the Commissioner of the New York City Department of Buildings. This position was the culmination of a successful legal career that stretched back across …

Read the full story »
[ by | Aug 6, 2014 3:57 pm | One Comment ]

Constellation Pharmaceuticals recently initiated a Phase 1 clinical trial that will test whether single-agent CPI-0610 is safe and effective as an anti-myeloma therapy.

The clinical trial is taking place at a several locations across the United States, and is open to multiple myeloma patients who have relapsed after at least one previous myeloma treatment regimen.

CPI-0610 is a small molecule that inhibits bromodomain and extra-terminal (BET) proteins, which are involved in regulating the cell cycle and cell death. Bromodomain inhibitors, which include the compound JQ1, have attracted attention in recent years as potential treatments for a range of different cancers, including multiple myeloma.

A Phase 1 clinical trial of CPI-0610 as a potential treatment for lymphoma has been ongoing since last summer. The Phase 1 trial in myeloma and another Phase 1 trial in patients with acute leukemias and myelodysplastic syndromes have been added based on preclinical research showing blood-related cancers may be highly sensitive to BET inhibition.

For more information about the trial, see the trial description at the U.S. clinical trial registry.

[ by | Aug 4, 2014 6:51 pm | 16 Comments ]
Kyprolis Succeeds In Phase 3 Relapsed Multiple Myeloma Trial – Approval Filings Planned For Europe And Other Countries

Amgen this morning announced initial results of its Phase 3 “ASPIRE” trial com­par­ing Kyprolis-Revlimid-dex­a­meth­a­sone to Revlimid-dex­a­meth­a­sone in pa­tients with relapsed multiple myeloma.

Patients in the trial who received the Kyprolis-Revlimid-dex­a­meth­a­sone com­bi­na­tion (KRd) had significantly longer progression-free survival (26.3 months) than patients who received only Revlimid and dex­a­meth­a­sone (Rd) (17.6 months).

There was also a trend in the results toward improved overall survival among the patients who received KRd versus those who did not. How­ever, the difference is not yet statistically significant.

The results of the trial are important for two …

Read the full story »
[ by | Jul 30, 2014 12:33 pm | 39 Comments ]
Remembering Arnold Goodman

The myeloma community has lost a courageous and inspiring soul.

Long-time Beacon columnist Dr. Arnold Goodman, known to most of his readers as just “Arnie,” passed away yesterday in the company of his family at the Moffitt Cancer Center in Tampa, Florida.

Arnie had been a physician for two decades, practicing as an ear, nose, and throat specialist, prior to his diagnosis with multiple myeloma in the spring of 2006. He continued his medical practice for three years after his diagnosis, eventually deciding to stop work due to the physical …

Read the full story »